B. Riley initiated coverage of Climb Bio (CLYM) with a Buy rating and $26 price target The firm cites the company’s “robust execution” in early-stage trials of two antibodies developed against two “high-value targets in a fast- expanding pool” of B-cell mediated rare kidney and autoimmune diseases for the Buy rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: